Potentiation of Ph⁺human cell lines to combining TKI and small-molecule BCL-2 inhibitors. Human Ph⁺ cell lines: OP-1 Ph⁺ B-ALL (A) TOM1 Ph⁺ B-ALL (B), and BV173 Ph⁺ CML blast crisis (C) cell lines were treated with navitoclax, IM, or DAS at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1, and BCL-X_L. For potentiation experiments, the percentage of viable cells was determined by annexin-V and PI negativity. Bars represent the average of 3 independent experiments, each done in triplicate, for each cell type, and the error bars denote the SEM. Asterisk (*) indicates P < .001 by 2-way analysis of variance with a Bon Ferroni posttest between treatments linked with horizontal line.